Transplantation & Cellular Therapy
Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Advertisement
Cecilia BrownTransplantation & Cellular Therapy | March 3, 2023
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
Read More
Cecilia BrownTransplantation & Cellular Therapy | March 2, 2023
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Cecilia BrownViewpoints | February 28, 2023
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 23, 2023
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Cecilia BrownMeeting News | February 21, 2023
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Cecilia BrownTransplantation & Cellular Therapy | February 21, 2023
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
Advertisement
Leah SherwoodTransplantation & Cellular Therapy | February 17, 2023
The study used natural language processing for computer-assisted review of electronic health records.
Cecilia BrownMyeloma | February 16, 2023
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
Cecilia BrownTransplantation & Cellular Therapy | February 10, 2023
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Cecilia BrownVideo Insights | February 8, 2023
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
Cecilia BrownMyeloma | January 25, 2023
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Cecilia BrownPrint | January 13, 2023
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Cecilia BrownTransplantation & Cellular Therapy | December 2, 2022
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Leah SherwoodTransplantation & Cellular Therapy | November 29, 2022
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Certain genetic features in tumor and plasma samples from patients with LBCL are associated with poor CD19-directed CAR-T...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
CD19-directed CAR T-cells led to a complete remission in around half of patients with relapsed/refractory CNS lymphoma.
Advertisement
Advertisement
Editorial Board